scholarly journals Brain activation patterns of female multiple sclerosis patients with voiding dysfunction

2020 ◽  
Vol 39 (3) ◽  
pp. 969-977
Author(s):  
Rose Khavari ◽  
Jessie Chen ◽  
Timothy Boone ◽  
Christof Karmonik
Keyword(s):  
Multiple Sclerosis ◽  
Voiding Dysfunction ◽  
Brain Activation ◽  
Activation Patterns ◽  
Multiple Sclerosis Patients

Brain activation that is modulated by the level of the integrity of corticospinal system in Multiple Sclerosis patients

2008 ◽  
Vol 1 (3) ◽  
pp. 307-308
Author(s):  
A. Steens ◽  
A. de Vries ◽  
J.H. van der Hoeven ◽  
D.J. Heersema ◽  
M.A.P. Heerings ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Activation ◽  
Corticospinal System ◽  
Multiple Sclerosis Patients

scholarly journals Change in Functional Brain Activation Patterns Induced by Olfactory Stimulation in Multiple Sclerosis

2020 ◽  
Vol Volume 16 ◽  
pp. 1451-1458
Author(s):  
Qingrong OuYang ◽  
Yinxu Wang ◽  
Yun-Wei Zhang ◽  
Ming Yu ◽  
Xiaoming Wang
Keyword(s):  
Multiple Sclerosis ◽  
Brain Activation ◽  
Olfactory Stimulation ◽  
Activation Patterns ◽  
Functional Brain

Brain activation patterns associated with paragraph learning in persons with multiple sclerosis: The MEMREHAB trial

2020 ◽  
Vol 154 ◽  
pp. 37-45
Author(s):  
Olga Boukrina ◽  
Ekaterina Dobryakova ◽  
Veronica Schneider ◽  
John DeLuca ◽  
Nancy D. Chiaravalloti
Keyword(s):  
Multiple Sclerosis ◽  
Brain Activation ◽  
Activation Patterns

Brain activation patterns elicited by the `Faces Symbol Test' — a pilot fMRI study

2008 ◽  
Vol 14 (3) ◽  
pp. 354-363 ◽  
Author(s):  
RH Grabner ◽  
F. Popotnig ◽  
S. Ropele ◽  
C. Neuper ◽  
F. Gorani ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Activation ◽  
Brain Regions ◽  
Screening Tests ◽  
Choice Test ◽  
Imaging Data ◽  
Attention And Executive Control ◽  
Experimental Conditions ◽  
Activation Patterns ◽  
Serial Addition

The Faces Symbol Test (FST) has recently been proposed as a brief and patient-friendly screening instrument for the assessment of cognitive dysfunction in patients with multiple sclerosis (MS). However, in contrast to well-established MS screening tests such as the Paced Auditory Serial Addition Test, the neural correlates of the FST have not been investigated so far. In the present study, we developed a functional MRI (fMRI) version of the FST to provide first data on brain regions and networks involved in this test. A sample of 19 healthy participants completed a version of the FST adapted for fMRI, requiring matching of faces and symbols in a multiple choice test and two further experimental conditions drawing on cognitive subcomponents (face matching and symbol matching). Imaging data showed a differential involvement of a fronto-parieto-occipital network in the three conditions. The most demanding FST condition elicited brain activation patterns related with sustained attention and executive control. These results suggest that the FST recruits brain networks critical for higher-order cognitive functions often impaired in MS patients. Multiple Sclerosis 2008; 14: 354—363. http://msj.sagepub.com

scholarly journals Therapeutic Effects of Noninvasive, Individualized, Transcranial Neuromodulation Treatment for Voiding Dysfunction in Multiple Sclerosis Patients: Study Protocol for a Pilot Clinical Trial

2021 ◽  
Author(s):  
Khue Tran ◽  
Zhaoyue Shi ◽  
Christof Karmonik ◽  
Blessy John ◽  
Hamida Rajab ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Functional Mri ◽  
Voiding Dysfunction ◽  
Post Treatment ◽  
Lower Urinary Tract Dysfunction ◽  
Therapeutic Effects ◽  
Functional Connections ◽  
Multiple Sclerosis Patients ◽  
The Brain

Abstract Background: Voiding dysfunction (VD) is a common neurogenic lower urinary tract dysfunction (NLUTD) in multiple sclerosis (MS) patients. Currently, the only effective management for VD and urinary retention in MS patients is catheterization, prompting us to look for novel therapeutic options beyond the bladder, such as the brain. Transcranial rotating permanent magnet stimulator (TRPMS) is a noninvasive, portable, multifocal neuromodulator that simultaneously modulates multiple cortical regions, enhancing or attenuating strengths of functional connections between these regions. The objective of this pilot clinical trial is to evaluate the therapeutic effects of TRPMS in modulating brain regions during voiding initiation and mitigating VD in female MS individuals.Methods: Ten adult female MS patients with VD (defined as having %post-void residual/bladder capacity (%PVR/BC) ≥ 40% or Liverpool nomogram percentile < 10%) will be recruited for this study. Concurrent urodynamic and functional MRI evaluation with a bladder filling/emptying task repeated three to four times will be performed at baseline and post-treatment. Predetermined regions of interest and their blood-oxygen-level-dependent (BOLD) activation at voiding initiation will be identified on each patient’s baseline anatomical and functional MRI scan, corresponding to the microstimulators placement on their individualized TRPMS treatment cap to either stimulate or inhibit these regions. Patients will receive ten 40-minute treatment sessions. Non-instrumented uroflow and validated questionnaires will also be collected at baseline and post-treatment to evaluate clinical improvement.Discussion: Despite the crucial role of the central nervous system in urinary control and its sensitivity to MS, there has been no treatment for urinary dysfunction targeting the brain centers that are involved in proper bladder function. This trial, to our knowledge, will be the first of its kind in humans to consider non-invasive and individualized cortical modulation for treating VD in MS patients. Results from this study will provide a better understanding of the brain control of neurogenic bladders and lay the foundation for a potential alternative therapy for VD in MS patients and other NLUTD in a larger neurogenic population in the future.Trial registration: This trial is registered at ClinicalTrials.Gov (NCT03574610, July 2, 2018, https://clinicaltrials.gov/ct2/show/NCT03574610) and Houston Methodist Research Institute IRB (PRO00019329).

scholarly journals Therapeutic Effects of Noninvasive, Individualized, Transcranial Neuromodulation Treatment for Voiding Dysfunction in Multiple Sclerosis Patients: Study Protocol for a Pilot Clinical Trial

2021 ◽  
Author(s):  
Khue Tran ◽  
Zhaoyue Shi ◽  
Christof Karmonik ◽  
Blessy John ◽  
Hamida Rajab ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Functional Mri ◽  
Voiding Dysfunction ◽  
Post Treatment ◽  
Lower Urinary Tract Dysfunction ◽  
Therapeutic Effects ◽  
Functional Connections ◽  
Multiple Sclerosis Patients ◽  
The Brain

Abstract Background: Voiding dysfunction (VD) is a common neurogenic lower urinary tract dysfunction (NLUTD) in multiple sclerosis (MS) patients. Currently, the only effective management for VD and urinary retention in MS patients is catheterization, prompting us to look for novel therapeutic options beyond the bladder, such as the brain. Transcranial rotating permanent magnet stimulator (TRPMS) is a noninvasive, portable, multifocal neuromodulator that simultaneously modulates multiple cortical regions, enhancing or attenuating strengths of functional connections between these regions. The objective of this pilot clinical trial is to evaluate the therapeutic effects of TRPMS in modulating brain regions during voiding initiation and mitigating VD in female MS individuals.Methods: Ten adult female MS patients with VD (defined as having %post-void residual/bladder capacity (%PVR/BC) ≥ 40% or Liverpool nomogram percentile < 10%) will be recruited for this study. Concurrent urodynamic and functional MRI evaluation with a bladder filling/emptying task repeated three to four times will be performed at baseline and post-treatment. Predetermined regions of interest and their blood-oxygen-level-dependent (BOLD) activation at voiding initiation will be identified on each patient’s baseline anatomical and functional MRI scan, corresponding to the microstimulators placement on their individualized TRPMS treatment cap to either stimulate or inhibit these regions. Patients will receive ten 40-minute treatment sessions. Non-instrumented uroflow and validated questionnaires will also be collected at baseline and post-treatment to evaluate clinical improvement.Discussion: Despite the crucial role of the central nervous system in urinary control and its sensitivity to MS, there has been no treatment for urinary dysfunction targeting the brain centers that are involved in proper bladder function. This trial, to our knowledge, will be the first of its kind in humans to consider non-invasive and individualized cortical modulation for treating VD in MS patients. Results from this study will provide a better understanding of the brain control of neurogenic bladders and lay the foundation for a potential alternative therapy for VD in MS patients and other NLUTD in a larger neurogenic population in the future.Trial registration: This trial is registered at ClinicalTrials.Gov (NCT03574610, July 2, 2018, https://clinicaltrials.gov/ct2/show/NCT03574610) and Houston Methodist Research Institute IRB (PRO00019329).

Sign in / Sign up

Export Citation Format

Share Document